Latest news with #ENVB
Yahoo
29-05-2025
- Business
- Yahoo
Enveric Biosciences announces results from EB-003 trial
Enveric Biosciences (ENVB) announced preclinical results for its lead neuroplastogen drug candidate, EB-003, in the Open Space Forced Swim Test, a preclinical mouse model of severe depression and despair. The Open Space Forced Swim Test, a psychiatric behavioral model, is designed to induce potent and enduring chronic depression-like states in mice, leading to reduced swim distance and increased periods of despair-induced immobility. In a study performed by a third-party lab, an oral dose of EB-003 at 30 mg/kg significantly reduced depression-like behavior within 30 minutes of administration. This was indicated by the enhanced distance travelled and reduced immobility of treated mice during forced swim sessions. These results were comparable to the therapeutic effects of Imipramine, an approved tricyclic antidepressant drug. A repeat study, conducted by the same third-party lab, produced consistent results, confirming 30 mg/kg as an efficacious oral dose for EB-003. The study also confirmed no adverse locomotor effects were observed at this dose. The study also performed a preliminary assessment of extended, daily dosing of EB-003 to determine any potential safety concerns for chronic therapeutic administration. Mice receiving a daily oral dose of EB-003 at 30 mg/kg for 22 days showed no adverse behavioral, physiological or neurological effects. These observations demonstrate acceptable tolerance to long-term systemic drug exposure and expand the range of EB-003 dosing strategies. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on ENVB: Disclaimer & DisclosureReport an Issue Psychedelic: atai Life Sciences reports Phase 2a study data on BPL-003 Enveric Biosciences files new provisional patent application VA secretary wants to find answers on psychedelics therapies, Politico says Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results Psychedelic: Enveric, Filament Health report earnings results
Yahoo
31-01-2025
- Business
- Yahoo
Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading
Enveric Biosciences (ENVB, Financials) priced a $5 million public offering, sending its shares down 40.51% to $2.32 in Friday's premarket trading. Warning! GuruFocus has detected 2 Warning Signs with ENVB. With each valued at $3.00, the offering comprises 1.67 million ordinary equity shares along with warrants. Subject to usual closing conditions, the business anticipates the deal to completion by February 3, 2025. Both exercisable at $3.00 per share, the offering consists of Series A and Series B warrants. The Series A warrants last five years; the Series B warrants expire in eighteen months. The only placement agency for the deal is H.C. Wainwright & Co. Before subtracting fees and expenditures, the total income is projected to be around $5 million. Enveric said it would use the money for general company needs, working capital, and product development. Under a registered statement on Form S-1, which the Securities and Exchange Commission deemed effective on Jan. 30, the offer is being undertaken. On the SEC's website will be a final prospectus accessible. Developing neuroplastogenic small-molecule therapies targeted at treating anxiety, depression, and addiction disorders is the specialty of Enveric Biosciences. Designed to encourage neuroplasticity without hallucinations, EB-003, the company's flagship medication candidate is getting ready for clinical testing. This article first appeared on GuruFocus.
